Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period

HIDEYA KASHIHARA, MITSUO SHIMADA, KOZO YOSHIKAWA, JUN HIGASHIJIMA, TOMOHIKO MIYATANI, TAKUYA TOKUNAGA, MASAAKI NISHI and CHIE TAKASU
Anticancer Research August 2018, 38 (8) 4901-4905; DOI: https://doi.org/10.21873/anticanres.12805
HIDEYA KASHIHARA
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kashihara.hideya@tokushima-u.ac.jp
MITSUO SHIMADA
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOZO YOSHIKAWA
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUN HIGASHIJIMA
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOHIKO MIYATANI
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKUYA TOKUNAGA
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAAKI NISHI
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIE TAKASU
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: The aim of this study was to investigate the effect of Roux-en-Y (RY) reconstruction on type 2 diabetes with gastric cancer in the early postoperative period. Patients and Methods: A total of 44 patients with gastric cancer with type 2 diabetes who underwent total gastrectomy (TG) or distal gastrectomy (DG) with Roux-en-Y reconstruction or DG with Bilroth I were enrolled. All three groups had their fasting glucose and daily insulin dose recorded preoperatively, on day 2 postoperatively (POD2) and at discharge. Results: The TG group showed low fasting glucose and daily insulin dose on POD2 compared to their preoperative state. On discharge, the fasting glucose and daily insulin dose were significantly lower in both TG and DG Roux-en-Y groups than preoperatively. Conclusion: Roux-en-Y reconstruction showed early improvement of type 2 diabetes regardless of any body weight loss. The effect of Roux-en-Y reconstruction in TG on type 2 diabetes was more remarkable than that of DG.

  • Roux-en-Y (RY)
  • total gastrectomy (TG)
  • early improvement

Diabetes mellitus is the third most common chronic non-communicable disease in the world and in Japan (1). This metabolic disease is characterized by elevated blood glucose and is caused by insulin insufficiency or dysfunction (2). Type 2 diabetes affects the metabolism of other tissues and organs, leading to a series of complications with severe consequences for quality of life (3, 4).

Recently, bariatric surgery has been adapted for morbid obesity or obesity with related co-morbidities such as type 2 diabetes and hyperlipidemia (5). A systematic review and meta-analysis showed an improvement in 76.8% of patients with type 2 diabetes who underwent bariatric surgery (6). In our previous report, duodenal-jejunal bypass was shown to improve type 2 diabetes and liver steatosis by enhancing glucogen like peptide-1 (GLP1) secretion through increasing serum bile acids and the proliferation of L cells in the ileum (7).

Few studies have reported the improvement of type 2 diabetes in patients with gastric cancer after gastrectomy (8). However, the effect in the early postoperative period remains unclear. The aim of this study was to investigate the effect of Roux-en-Y (RY) reconstruction on type 2 diabetes in the early postoperative period.

Patients and Methods

From January 2012 through December 2015, 44 patients with type 2 diabetes (37 men and seven women; mean age 70 years; age range from 51 to 88 years) were referred to our Institution for treatment of gastric cancer.

Thirty-five patients with gastric cancer with type 2 diabetes who underwent gastrectomy with RY [(total gastrectomy (TG)=20; distal gastrectomy (DG)=15) and nine with Bilroth I (B-I) reconstruction. The patients underwent DG with Bilroth I or RY reconstruction, or TG with RY reconstruction according to the size and location of the tumor. In RY reconstruction, the jejunum was divided at 20 cm distal from the Treitz ligament; the distal limb of the jejunum was anastomosed to the esophagus; and jejuno-jejunostomy was performed at 40 cm distal from the esophago-jejunal anastomosis.

After gastrectomy, the patients were given only water to drink for the first 2 days postoperatively. On day 4 postoperatively they started eating. When recovery proceeded according to plan, they were discharged from our hospital on day 10 to 14 postoperatively.

Statistical analysis. The paired t-test or Bonferroni's test were used for statistical analysis of the three groups in the patient characteristics, fasting glucose, daily insulin dose and changes in body weight. For all tests, a value of p<0.05 was interpreted as significant. Values for continuous variables are expressed as the mean±the standard deviation (SD).

Results

Table I shows the characteristics of the patients in the three groups. There was no significant difference in body mass index (BMI), hemoglobin A1c (HbA1c) and the use of anti-diabetic agents. However, the proportion of patients who underwent laparoscopic surgery in the B-I group was significantly higher in than the other two groups.

Figure 1 shows the time-dependent change in fasting glucose level after gastrectomy in the three groups. In the TG RY group, the fasting glucose level on day 2 postoperatively (POD2) was significantly lower than that recorded preoperatively (p<0.05). The level was reduced by 9%. The TG RY group also showed further decrease of fasting glucose on discharge. Although the fasting glucose level of the DG RY group did not significantly differ preoperatively from that at POD2 (p=0.23), at discharge it was significantly lower than preoperatively (p<0.01). However, the B-I group did not show this effect (both p>0.05).

Figure 2 shows time-dependent change in daily insulin dose after gastrectomy in the three types of reconstruction. On POD2, the. daily insulin dose for the TG RY group was significantly lower compared with that recorded preoperatively (p<0.05). DG RY and B-I groups did not show this effect. Daily insulin dose on discharge from hospital was significantly lower compared with that recorded preoperatively for all groups (p<0.05).

In the three groups, there was no significant difference regarding changes in patient body weight during their stay in hospital (p>0.05; Figure 3).

Discussion

This study was designed to investigate the effect of RY reconstruction on type 2 diabetes in the early postoperative period. The fasting glucose and daily insulin dose of the TG RY group on POD-2 were significantly lower than that recorded preoperatively regardless of body weight loss. However, the DG RY and B-I reconstruction led to an early postoperative improvement of type 2 diabetes.

Several studies reported that patients with type 2 diabetes had a high risk of malignant tumors, especially colorectal, liver, pancreatic, breast, endometrial and bladder cancer (9-13). The risk of gastric cancer is also increased in patients with type 2 diabetes (14). Wei et al. reported that pre-existing diabetes was associated with poor postoperative prognosis when the diabetes became worse after curative gastrectomy for gastric cancer (15). Insulin was found to enhance the effect of epidermal growth factor on the proliferation of gastric epithelial cells (16). Yoshizawa et al. demonstrated that hyperinsulinemia and hyperleptinemia promote gastric carcinogenesis (17). Regarding gastric cancer, patients with uncontrolled type 2 diabetes might have more progressive tumors and worse prognosis. However, patients with cured or improved type 2 diabetes after radical gastrectomy are reported to show better prognosis than patients with worsened or same status of type 2 diabetes (5-year overall survival rate: 62.1% vs. 23.4% respectively) (15).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Characteristics of patients in the three groups.

In a previous study, the rates of improvement of type 2 diabetes in patients who underwent DG with B-I or B-II, and TG with RY reconstruction at 1 month postoperatively were 23.0, 52.3, and 82.5%, respectively (18). Our study also showed the effect of TG RY on type2 diabetes was more remarkable than that of DG RY, as can be seen from Figures 1 and 2. However, as no report regarding the early postoperative effect of RY on type 2 diabetes exists as far as we aware, this study is the first report of the effect of RY reconstruction on type 2 diabetes in the early postoperative period.

Several types of bariatric surgery, including sleeve gastrectomy, gastric banding and gastric bypass, are currently performed and these procedures have showed not only body weight loss but also improvement of type 2 diabetes (19). Seki et al. reported that a case with sleeve gastrectomy with duodenojejunal bypass had a glucose level below 200 mg/ml 100% of the time after POD3 and no diabetic medication on or after POD2 (20). Sleeve gastrectomy suppressed plasma ghrelin and increased insulin, GLP1 and peptide YY, whereas duodenal jejunal bypass increased ghrelin, insulin, GLP1 and peptide YY (21).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The time-dependent change of fasting glucose level after three types of reconstruction with gastrectomy for patients with gastric cancer. RY: Roux-en-Y reconstruction; TG: total gastrectomy; DG: distal gastrectomy; B-I: Bilroth I reconstruction; POD2: postoperative day 2. Boxes indicate the interquartile range, bars indicate the SD, lines indicate the median, and circles indicate the outlier.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Daily insulin dose during hospital stay after three types of reconstruction with gastrectomy for patients with gastric cancer. RY: Roux-en-Y reconstruction; TG: total gastrectomy; DG: distal gastrectomy; B-I: Bilroth I reconstruction; POD2: postoperative day 2. Boxes indicate the interquartile range, bars indicate the SD, lines indicate the median, and circles indicate the outlier.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Body weight change during hospital stay after three types of reconstruction with gastrectomy for patients with gastric cancer. RY: Roux-en-Y reconstruction; TG: total gastrectomy; DG: distal gastrectomy; B-I: Bilroth I reconstruction; POD2: postoperative day 2. Boxes indicate the interquartile range, bars indicate the SD, lines indicate the median, and circles indicate the outlier.

Ghrelin is well-known to be secreted by the empty (fasting) stomach in order to enhance food intake (22). Endocrine ghrelin cells are located in the fundus and body of the stomach (23). Ghrelin directly interacts with islet β-cells, which leads to suppression of insulin release (24). Regarding the difference between TG RY and DG RY in the improvement of diabetes, a lower level of ghrelin after TG compared with that after DG might lead to higher secretion of insulin.

Bypass surgery improved type 2 diabetes via enhanced GLP1, which stimulatea insulin secretion (7). Regarding the difference between RY and B-I with DG in the improvement of diabetes, a higher level of GLP1 after RY compared to that after B-I might lead to higher secretion of insulin.

In conclusion, RY reconstruction showed early improvement of type 2 diabetes regardless of body weight loss. The effect of TG RY on diabetes was more remarkable than that of DG RY.

Acknowledgements

The Authors are grateful to the staff at the Department of Surgery, Institute of Health Biosciences, University of Tokushima, for important contributions.

Hideya Kashihara and the other co-authors have no conflict of interest in regard to this study.

  • Received May 28, 2018.
  • Revision received June 6, 2018.
  • Accepted July 9, 2018.
  • Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Shaw JE,
    2. Sicree RA,
    3. Zimmet PZ
    : Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14, 2010.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Stumvoll M,
    2. Goldstein BJ,
    3. van Haeften TW
    : Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 365: 1333-1346, 2005.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Tanaka S,
    2. Tanaka S,
    3. Iimuro S,
    4. Yamashita H,
    5. Katayama S,
    6. Akanuma Y,
    7. Yamada N,
    8. Araki A,
    9. Ito H,
    10. Sone H,
    11. Ohashi Y,
    12. Japan Diabetes Complications Study Group,
    13. Japanese Elderly Diabetes Intervention Trial Group
    : Predicting macro-and microvascular complications in type 2 diabetes: The Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care 36: 1193-1199, 2013.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Rigalleau V,
    2. Cougnard-Gregoire A,
    3. Nov S,
    4. Gonzalez C,
    5. Maury E,
    6. Lorrain S,
    7. Gin H,
    8. Barberger-Gateau P
    : Association of advanced glycation end-products and chronic kidney disease with macroangiopathy in type 2 diabetes. J Diabetes Complications 29: 270-274, 2015.
    OpenUrl
  5. ↵
    1. Gilbert EW,
    2. Wolfe BM
    : Bariatric surgery for the management of obesity: state of the field. Plast Reconstr Surg 130: 948-954, 2012.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Schauer PR,
    2. Burguera B,
    3. Ikramuddin S,
    4. Cottam D,
    5. Gourash W,
    6. Hamad G,
    7. Eid GM,
    8. Mattar S,
    9. Ramanathan R,
    10. Barinas-Mitchel E,
    11. Rao RH,
    12. Kuller L,
    13. Kelley D
    : Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238: 467-484, 2003.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kashihara H1,
    2. Shimada M,
    3. Kurita N,
    4. Sato H,
    5. Yoshikawa K,
    6. Higashijima J,
    7. Chikakiyo M,
    8. Nishi M,
    9. Takasu C
    : Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids. J Gastroenterol Hepatol 30(2): 308-315, 2015.
    OpenUrl
  8. ↵
    1. Kim JW,
    2. Cheong JH,
    3. Hyung WJ,
    4. Choi SH,
    5. Noh SH
    : Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol 18: 49-54, 2012.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Schrauder MG,
    2. Fasching PA,
    3. Häberle L,
    4. Lux MP,
    5. Rauh C,
    6. Hein A,
    7. Bayer CM,
    8. Heusinger K,
    9. Hartmann A,
    10. Strehl JD,
    11. Wachter DL,
    12. Schulz-Wendtland R,
    13. Adamietz B,
    14. Beckmann MW,
    15. Loehberg CR
    : Diabetes and prognosis in a breast cancer cohort. J Cancer Res Clin Oncol 137: 975-983, 2011.
    OpenUrlCrossRefPubMed
    1. Larsson SC,
    2. Orsini N,
    3. Wolk A
    ,, Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679-1687, 2005.
    OpenUrlCrossRefPubMed
    1. El-Serag HB,
    2. Hampel H,
    3. Javadi F
    : The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4: 369-380, 2006.
    OpenUrlCrossRefPubMed
    1. Friberg E,
    2. Orsini N,
    3. Mantzoros CS,
    4. Wolk A
    : Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia 50: 1365-1374, 2007.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Woolcott CG,
    2. Maskarinec G,
    3. Haiman CA,
    4. Henderson BE,
    5. Kolonel LN
    : Diabetes and urothelial cancer risk: the multiethnic cohort study. Cancer Epidemiol 35: 551-554, 2011.
    OpenUrlPubMed
  11. ↵
    1. Coughlin SS,
    2. Calle EE,
    3. Teras LR,
    4. Petrelli J,
    5. Thun MJ
    : Diabetes mellitus as a predictor of cancer mortality in a large cohort of us adults. Am J Epidemiol 159: 1160-1167, 2004.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Wei ZW,
    2. Li JL,
    3. Wu Y,
    4. Xia GK,
    5. Schwarz RE,
    6. He YL,
    7. Zhang CH
    : Impact of pre-existing type-2 diabetes on patient outcomes after radical resection for gastric cancer: a retrospective cohort study. Dig Dis Sci 59(5): 1017-1024, 2014.
    OpenUrl
  13. ↵
    1. Ogihara S,
    2. Yamada M,
    3. Saito T,
    4. Shono M,
    5. Rokutan K
    : Insulin potentiates mitogenic effect of epidermal growth factor on cultured guinea pig gastric mucous cells. Am J Physiol 271: G104-G112, 1996.
    OpenUrlPubMed
  14. ↵
    1. Yoshizawa N,
    2. Yamaguchi H,
    3. Yamamoto M,
    4. Shimizu N,
    5. Furihata C,
    6. Tatematsu M,
    7. Seto Y,
    8. Kaminishi M
    : Gastric carcinogenesis by N-methyl-N-nitrosourea is enhanced in db/db diabetic mice. Cancer Sci 100: 1180-1185, 2009.
    OpenUrlPubMed
  15. ↵
    1. Zhu Z,
    2. Shan X,
    3. Cheng Y,
    4. Xu J,
    5. Fu H,
    6. Wang W,
    7. Yan R,
    8. Cai Q
    : Clinical course of diabetes after gastrectomy according to type of reconstruction in patients with concurrent gastric cancer and type 2 diabetes. Obes Surg 25: 673-679, 2015.
    OpenUrl
  16. ↵
    1. Pories WJ,
    2. Swanson MS,
    3. MacDonald KG,
    4. Long SB,
    5. Morris PG,
    6. Brown BM,
    7. Barakat HA,
    8. deRamon RA,
    9. Israel G,
    10. Dolezal JM
    : Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222(3): 339-350, 1995.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Seki Y,
    2. Kasama K,
    3. Umezawa A,
    4. Kurokawa Y
    : Laparoscopic sleeve gastrectomy with duodenojejunal bypass for type 2 diabetes mellitus. Obes Surg 26(9): 2035-2044, 2016.
    OpenUrl
  18. ↵
    1. Peterli R,
    2. Wölnerhanssen B,
    3. Peters T,
    4. Devaux N,
    5. Kern B,
    6. Christoffel-Courtin C,
    7. Drewe J,
    8. von Flüe M,
    9. Beglinger C
    : Improvement in glucose metabolism after bariatric surgery: Comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: A prospective randomized trial. Ann Surg 250(2): 234-241, 2009.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Konturek SJ,
    2. Konturek JW,
    3. Pawlik T,
    4. Brzozowski T
    : Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 55: 137-154, 2004.
    OpenUrlPubMed
  20. ↵
    1. Date Y,
    2. Kojima M,
    3. Hosoda H,
    4. Sawaguchi A,
    5. Mondal MS,
    6. Suganuma T,
    7. Matsukura S,
    8. Kangawa K,
    9. Nakazato M
    : Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141: 4255-4261, 2000.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Dezaki K,
    2. Damdindorj B,
    3. Sone H,
    4. Dyachok O,
    5. Tengholm A,
    6. Gylfe E,
    7. Kurashina T,
    8. Yoshida M,
    9. Kakei M,
    10. Yada T
    : Ghrelin attenuates cAMP-PKA signaling to evoke insulinostatic cascade in islet β-cells. Diabetes 60(9): 2315-2324, 2011.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (8)
Anticancer Research
Vol. 38, Issue 8
August 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period
HIDEYA KASHIHARA, MITSUO SHIMADA, KOZO YOSHIKAWA, JUN HIGASHIJIMA, TOMOHIKO MIYATANI, TAKUYA TOKUNAGA, MASAAKI NISHI, CHIE TAKASU
Anticancer Research Aug 2018, 38 (8) 4901-4905; DOI: 10.21873/anticanres.12805

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period
HIDEYA KASHIHARA, MITSUO SHIMADA, KOZO YOSHIKAWA, JUN HIGASHIJIMA, TOMOHIKO MIYATANI, TAKUYA TOKUNAGA, MASAAKI NISHI, CHIE TAKASU
Anticancer Research Aug 2018, 38 (8) 4901-4905; DOI: 10.21873/anticanres.12805
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • Roux-en-Y (RY)
  • total gastrectomy (TG)
  • early improvement
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire